Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (214)	2/24/1999 8:34:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

Harold: I've worked extensively with this antibody, during quality control work at PharMingen. I've also worked a bit with a demyelinating model in SJL mice. However, I'm not quite certain of what they're trying to say here, so I've decided that I should read the entire paper before commenting (I saw the abstract posted in the BGEN thread, as you know). So, I think that I need to hit a medical library before opening mouth and inserting foot. :-) I still stand on what I've said previously.... while I expect anti-CD40L to be a blockbuster agent, I believe that the proposed mechanism for 507 is superior for at least certain diseases. The relative lack of preclinical data for 507 could reflect the expression of the epitope only on human, gorilla and chimp cells (one can't do experiments short of clinicals in humans, which, according to the MEDI conference call, are going well). There are experiments in rats that indicate, to me, that a similar antibody may have been described there. Open question. Thanks! Rick